KAHF Biotech, Inc.
Building a target-centric therapeutic ecosystem for next-generation cancer treatment
https://wefunder.com/kahf.biotech.inc
Total raised on Wefunder: 62000
Total investors: 10
Quick facts
- A novel target in PDAC with limited prior characterization and promising preclinical validation
- Dual therapeutic strategy: blocks metastasis early and kills tumors in late-stage disease
- Capital-efficient plan: lead antibody development achievable at low cost
- Platform approach expandable to multiple solid tumors expressing the same receptor
- Lead antibody can be expanded into ADC, CAR-T cells, and Degrader Antibody conjugates (DACs)
- Founded by PhD cancer scientist with deep expertise in cancer therapeutic development platforms